PATH, Sexual and Reproductive Health, Seattle, WA, USA; CIBER Epidemiologia y Salud Publica, Madrid, Spain.
Unit of Infections and Cancer-Information and Interventions, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Curr Opin Virol. 2019 Dec;39:16-22. doi: 10.1016/j.coviro.2019.06.006. Epub 2019 Aug 2.
Since 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a similar impact. In this review, we will summarize the compelling evidence of the impact of vaccines in reducing the burden of HPV-related disease. The data support additional efforts to make HPV vaccines widely available to adolescent girls in the countries that bear the vast majority of cervical cancer-related morbidity and mortality.
自 2006 年以来，已有 115 个国家和地区引入了人乳头瘤病毒（HPV）疫苗接种计划。已经开展了一些工作来评估 HPV 疫苗的影响。许多国家，主要是高收入国家和高筛查覆盖率国家，已经报告了 HPV 疫苗对 HPV 相关疾病的明显影响。其他国家，主要是低收入和中等收入国家，正在引入 HPV 疫苗来控制 HPV 疾病，这无疑将产生类似的影响。在这篇综述中，我们将总结疫苗在减轻 HPV 相关疾病负担方面的有力证据。这些数据支持进一步努力，使 HPV 疫苗在承担绝大多数宫颈癌相关发病率和死亡率的国家广泛提供给少女。
